Pertuzumab Use in the Adjuvant Setting: Why Not?
- PMID: 28095149
- DOI: 10.1200/JCO.2016.68.6212
Pertuzumab Use in the Adjuvant Setting: Why Not?
Comment in
-
Reply to L. Del Mastro and A. Prat.J Clin Oncol. 2017 Apr 1;35(10):1139. doi: 10.1200/JCO.2016.70.9758. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095161 No abstract available.
Comment on
-
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18. J Clin Oncol. 2016. PMID: 27091714
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
